Ignite Creation Date:
2024-05-06 @ 4:16 PM
Last Modification Date:
2024-10-26 @ 2:07 PM
Study NCT ID:
NCT04935372
Status:
RECRUITING
Last Update Posted:
2024-01-12
First Post:
2021-06-08
Brief Title:
β-AARC Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline
Sponsor:
Barcelonabeta Brain Research Center Pasqual Maragall Foundation
Organization:
Barcelonabeta Brain Research Center Pasqual Maragall Foundation
Study Overview
Official Title:
β-AARC Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
β-AARC
Brief Summary:
The overall cross-sectional objective of this study is to detect and describe the profile of AD-related blood biomarkers in a population with SCD including individuals with MCI with the ultimate goal of investigating their capacity to predict underlying AD pathology Longitudinally the β-AARC_BBRC2021 study fundamentally aims at assessing the ability of AD-related blood-based biomarkers to predict disease progression in the Alzheimers continuum
To achieve these cross-sectional and longitudinal objectives an exhaustive set of clinical risk factors cognitive mental health and neuroimaging data will be collected as well as blood and CSF samples from which AD-related fluid biomarkers will be determined
As a secondary objective we will investigate the efficacy and accuracy of the Altoida NMI as a novel digital biomarker for identifying patients with SCD or MCI that have underlying AD pathology cross-sectionally and to test the capacity of the Altoida NMI to track disease progression in these popoulations longitudinally
To achieve these cross-sectional and longitudinal objectives an exhaustive set of clinical risk factors cognitive mental health and neuroimaging data will be collected as well as blood and CSF samples from which AD-related fluid biomarkers will be determined
As a secondary objective we will investigate the efficacy and accuracy of the Altoida NMI as a novel digital biomarker for identifying patients with SCD or MCI that have underlying AD pathology cross-sectionally and to test the capacity of the Altoida NMI to track disease progression in these popoulations longitudinally
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None